… of erlotinib with standard chemotherapy could enhance survival in chemotherapy-naïve
patients with advanced or metastatic non–small-cell lung cancer (NSCLC). Erlotinib has been …

… cancer and a minor response was observed in a minimally pretreated patient with non-small
cell lung cancer … stomach, skin and non-small cell lung cancers. Analysis of normal skin and …

… increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer. …
with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent nonsmall cell lung cancer…

… erlotinib … Lung Cancer Symptom Scale). Sample size of 1050 was based on 80% power to
detect a 25% benefit in OS, α=0.05. Results: 1059 pts were randomized / treated (526 erlotinib…

… Erlotinib hydrochloride is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,…
erlotinib hydrochloride (27.3, 109.3, or 164 mg) equivalent to 25, 100, or 150 mg of erlotinib. …

… Pts who reported never smoking in the erlotinib arm (n=69) had an … erlotinib with CP did
not confer an advantage in OS over CP alone in all enrolled NSCLC pts, the addition of erlotinib …

… schedule of erlotinib and pemetrexed for the treatment of relapsed non–small cell lung cancer
(… Experimental Design: Human NSCLC cell lines, with variable expression of the known …

… Erlotinib (Tarceva) is a reversible and highly specific inhibitor … -positive non-small cell lung
cancer after failure of platinum-… severity is predictive of increased survival with erlotinib HCl. …

… In phase II clinical studies, oral erlotinib monotherapy has shown antitumor activity in
patients with advanced non–small cell lung cancer, head and neck cancer, and ovarian …

… Non-small cell lung cancer (NSCLC) patients with sensitizing mutations in the exons 18–21 …
Hence, tyrosine kinase inhibitors (TKIs) such as erlotinib (ETB) have commonly been used …